Article
PLGA Microspheres vs. Nanoparticles — CMC Strategy Divergence for Depot Injectables and the PSG Framework
PLGA microspheres and PLGA nanoparticles are made from the same polymer, encapsulate the same drug candidates, and release their payload by the same hydrolytic degradation mechanism. The regulatory…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
PLGA Microspheres vs. Nanoparticles — CMC Strategy Divergence for Depot Injectables and the PSG Framework
PLGA microspheres and PLGA nanoparticles are made from the same polymer, encapsulate the same drug candidates, and release their payload by the same hydrolytic degradation mechanism. The regulatory…
Article
Polymeric Nanocrystals and Nanosuspensions — Particle Engineering CMC for BCS II-IV Drug Candidates
The pharmaceutical rationale for a nanosuspension is straightforward: reduce particle size to increase surface area, increase surface area to increase dissolution rate, increase dissolution rate to improve oral…
Article
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers — CMC Differentiation from PLGA NPs at FDA Review
Solid lipid nanoparticles are constructed from the same regulatory logic as PLGA nanoparticles — a matrix that encapsulates a drug, a size below 200 nm, and a surface…
Article
PNP Future Trends: Stimuli-Responsive Systems, mRNA Competition, LNP Convergence
Polymer nanoparticle drug delivery is not a mature field. The approved PLGA microsphere products represent one chapter in a technology that is actively generating the next chapters: stimuli-responsive…
Article
Dendrimers and Polymeric Micelles: CMC for Next-Generation Nanoarchitectures
PLGA nanoparticles represent the established, well-precedented tier of polymer nanoparticle drug delivery. Beyond them lies a second tier — dendrimers and polymeric micelles — that offer properties unavailable…
Article
Surface Engineering: PEGylation, Targeting Ligands, CMC Characterization
The surface of a polymer nanoparticle is the interface between the drug delivery system and the biological environment into which it is injected. What is on that surface…
Article
Regulatory Pathway: NDA, 505(b)(2), FDA PSG Precedents, and EMA Navigation
Polymer nanoparticle drug products do not have a dedicated regulatory pathway at FDA or EMA. They are regulated as drugs — with the same requirements that apply to…
Article
PLGA Stability: Autocatalytic Hydrolysis, Accelerated Design Limits, Lyophilization
Polymer nanoparticles built on PLGA are by design unstable. The polymer backbone degrades by ester bond hydrolysis — and that degradation is the very mechanism by which the…
Article
PNP Specifications: Justified Acceptance Criteria for a Complex Drug Product
FDA's classification of polymer nanoparticle drug products as "complex drug products" is not simply a regulatory label. It is a description of an analytical reality: the product's identity,…
Article
In Vitro Drug Release: IVIVC and Regulatory Science for a Method Without a Monograph
Of all the CMC challenges in polymer nanoparticle drug product development, in vitro drug release testing is the most technically difficult, the most consequential for the regulatory submission…
Article
Characterizing Polymer Nanoparticles: Why DLS Misleads and AF4-MALS Reveals
Dynamic light scattering is the most widely used analytical method in nanoparticle characterization, and it is the method most likely to mislead you about the actual quality of…
Article
PNP Manufacturing: Nanoprecipitation, Emulsification, Scale-Up CPPs
The method by which a polymer nanoparticle is manufactured is not just a process decision — it is a formulation decision that determines drug loading efficiency, encapsulation mechanism,…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.